GT Biopharma Inc

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.

BEVERLY HILLS, Calif., Nov. 30, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that an abstract was accepted for presentation at the upcoming European Society for Medical Oncology ("ESMO") Immuno-Oncology ("IO") Congress 2021 to be held December 8-11, 2021 in Geneva Switzerland.

GT Biopharma Abstract on Novel B7-H3 Immune Checkpoint Targeting Broad Spectrum Solid and Hematologic Malignancies Accepted for Presentation at ESMO IO Congress 2021

BEVERLY HILLS, Calif., Nov. 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that Michael Breen, Executive Chairman and Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim Chief Executive Officer will be hosting a Management Update Conference call on Tuesday, November 30 th at 4:30PM Eastern Time.

GT BioPharma to Host a Management Update Conference Call

GT Biopharma is an early-stage oncology company with one clinical asset. GT Biopharma will likely shift focus to their 2nd generation therapies, which are still preclinical.

GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness

BEVERLY HILLS, Calif., Nov. 10, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE platform, today announced third quarter 2021 results for the period ended September 30, 2021.

GT BioPharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update

BEVERLY HILLS, Calif., Nov. 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary Tri-specific natural killer (NK) cell engager, TriKE® platform, today announced a restructuring of its executive management team.

GT Biopharma Announces Executive Leadership Transition to Implement Next Phase of Strategic Journey

The heavy selling pressure might have exhausted for OXIS International Inc. (GTBP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

OXIS International Inc. (GTBP) Loses 32.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

BEVERLY HILLS, Calif., Sept. 20, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE platform, today announced Dr. Jeffrey Miller's mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021.

GT BioPharma's Next Generation Camelid TriKE® Nanobody Platform Highlighted at ESMO Congress 2021

OXIS International Inc. (GTBP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

OXIS International Inc. (GTBP) Moves to Buy: Rationale Behind the Upgrade

BEVERLY HILLS, Calif., Sept. 15, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE protein biologic technology platform, today announced that Jeffrey Miller, MD, University of Minnesota Medical School, Professor of Medicine, Division of Hematology, Oncology and Transportation will present a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021 to be held virtually September 16-21.

GT Biopharma Announces Updated Positive Safety Data From Phase 1 GTB-3550 Monotherapy TriKE™ Trial an Investigational Immunotherapy for Refractory Cancers to be Presented at ESMO Congress 2021

BEVERLY HILLS, Calif., Sept. 13, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today, announces the advancement of GTB-3650 into IND-enabling studies, with which it plans to supplant the ongoing Phase 1 program with GTB-3550.

GT Biopharma Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies

BEVERLY HILLS, Calif., Sept. 9, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that the United States Patent and Trademark Office (USPTO) has issued 2 new patents: Patent No.

GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform Technologies

BEVERLY HILLS, Calif., Sept. 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today that Anthony Cataldo, Chairman & CEO,  Dr. Greg Berk, President of R&D and Chief Medical Officer, and Dr. Jeff Miller, Consulting Chief Scientific Officer will be presenting and hosting one-on-one meetings at the upcoming H.C.

GT Biopharma to Present at Upcoming September Investor Conferences

BEVERLY HILLS, Calif., Aug. 23, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® protein biologic technology platform, today announced the promotion of Gregory Berk, M.D.

GT Biopharma Announces the Promotion of Dr. Gregory Berk to President of Research & Development and Chief Medical Officer

GT Biopharma, Inc. (GTBP) CEO Tony Cataldo on Q2 2021 Results - Earnings Call Transcript

Announced Positive Interim Data Results Demonstrating Substantial Reduction in AML/MDS Cancer Cells… The post GT Biopharma Provides Second Quarter 2021 Business Update appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

GT Biopharma Provides Second Quarter 2021 Business Update.

BEVERLY HILLS, Calif., Aug. 13, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE®) protein biologic technology platform, today provided a general business update of events in the second quarter ending June 30, 2021.

GT Biopharma Provides Second Quarter 2021 Business Update

Dynavax Technologies

iShares Nasdaq Biotechnology ETF

Inovio Pharmaceuticals

Health Care Select Sector SPDR Fund

Merck's FDA and coronavirus vaccine news sparked momentum in biotech stocks today. Here are 4 to watch.

Former Penny Stocks To Watch After Merck's (MRK) Latest FDA Win

Agenus

Is it time to add biotech stocks to your list this year? The post Hot Biotech Stocks That Deserve Your Attention In August 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Biotech Stocks That Deserve Your Attention In August 2021

BEVERLY HILLS, Calif., Aug. 6, 2021 /PRNewswire/ — GT Biopharma, Inc. (“GT… The post GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results.

BEVERLY HILLS, Calif., Aug. 6, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that the management team will host a conference call to discuss second quarter 2021 financial results and general business updates on August 13, 2021 at 8:30 a.m.

GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results

Novavax

Pacific Biosciences of California

Cassava Sciences Inc

Have penny stocks presented some of the biggest opportunities in the stock market? The post Are Penny Stocks Worth It?

Are Penny Stocks Worth It? 5 That Deserve Your Attention Now

The stock price of GT Biopharma, Inc. (NASDAQ: GTBP) increased by over 6% pre-market. This is why it happened.

GTBP Stock Price Increases Over 6% Pre-Market: Why It Happened

POTENTIAL TREATMENT OF SEVERAL SOLID TUMOR CANCERS INCLUDING: NON-SMALL CELL LUNG CANCER,… The post GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™ appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™.

BEVERLY HILLS, Calif., Aug. 3, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on developing target-directed, tri-specific Natural Killer (NK) cell engager therapies (TriKE™) incorporating interleukin 15 (IL-15) for the treatment of cancer, announced preclinical results for GTB-5550, its B7H3 TriKE™ product candidate as a prospective therapy for the treatment of several different types of cancers.

GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™

Annovis Bio

Are penny stocks worth it? Take a look at these 3 seeing explosive moves this year.

News for GT Biopharma Inc Stock (GTBP)